Cytomx Therapeutics, Inc.

Annie Yang Weaver

Luc Roland Desnoyers

Jason Gary Sagert

Jonathan Alexander Terrett

Shweta Singh

James William West

Tony Liang

Kimberly Ann Tipton

The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.

Antibodies that bind activatable antibodies and methods of use thereof

The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Growing community of inventors

San Mateo, CA, United States of America

Annie Yang Weaver